Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  AcelRx Pharmaceuticals Inc    ACRX

ACELRX PHARMACEUTICALS INC (ACRX)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/14/2018 09/17/2018 09/18/2018 09/19/2018 09/20/2018 Date
3.4(c) 3.45(c) 3.75(c) 3.7(c) 3.7(c) Last
662 348 730 800 974 015 642 746 386 450 Volume
0.00% +1.47% +8.70% -1.33% 0.00% Change
More quotes
Financials (USD)
Sales 2018 8,03 M
EBIT 2018 -32,5 M
Net income 2018 -47,7 M
Debt 2018 -
Yield 2018 -
Sales 2019 18,3 M
EBIT 2019 -41,3 M
Net income 2019 -51,1 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 27,9x
Capi. / Sales2019 12,2x
Capitalization 224 M
More Financials
Company
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of acute pain.Its products include DSUVIA and ZALVISO.The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and... 
More about the company
Surperformance© ratings of AcelRx Pharmaceuticals Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACELRX PHARMACEUTICALS INC
09/20ACELRX PHARMACEUTICALS : Announces Date of FDA Advisory Committee Meeting for DS..
AQ
09/13ACELRX PHARMACEUTICALS : Researchers Submit Patent Application, "Apparatus And M..
AQ
09/13ACELRX PHARMACEUTICALS : Announces Date of FDA Advisory Committee Meeting for DS..
AQ
09/11ACELRX PHARMACEUTICALS : Announces Date of FDA Advisory Committee Meeting for DS..
PR
08/23ACELRX PHARMACEUTICALS : to Participate at Two Upcoming Investor Events in Septe..
PR
08/22ACELRX PHARMACEUTICALS : to Present at the 2018 Military Health System Research ..
AQ
08/20ACELRX PHARMACEUTICALS : to Present at the 2018 Military Health System Research ..
PR
08/16ACELRX PHARMACEUTICALS : Announces Full Exercise of Underwriters' Option to Purc..
AQ
08/14ACELRX PHARMACEUTICALS : Announces Full Exercise of Underwriters' Option to Purc..
AQ
08/08ACELRX PHARMACEUTICALS : Announces Full Exercise of Underwriters' Option to Purc..
PR
More news
Sector news : Bio Therapeutic Drugs
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
09/11AcelRx announces date of FDA advisory committee meeting for DSUVIA  
09/11$ACRX PR for Oct 12 DSUVIA AdComm.  
09/11$ACRX AcelRx Announces Date of FDA Advisory Committee Meeting for DSUVIA™ Fro.. 
09/09AcelRx Pharmaceuticals Inc $ACRX Receives Average Recommendation of “Buy” fro.. 
09/05$ACRX New Form 4 for AcelRx Pharmaceuticals From our Stock News Alerts App 
More tweets
Qtime:32
News from SeekingAlpha
09/18Senate passes opioid crisis bill 
09/13AcelRx Finally Has An AdCom Date. Time For A Run Up? 
09/11AcelRx announces date of FDA advisory committee meeting for DSUVIA 
09/07Senate vote approaches on bill to combat opioid crisis 
08/29FDA updates on multifaceted plan to combat opioid crisis 
Chart ACELRX PHARMACEUTICALS INC
Duration : Period :
AcelRx Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACELRX PHARMACEUTICALS INC
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 5,60 $
Spread / Average Target 51%
EPS Revisions
Managers
NameTitle
Vincent J. Angotti Chief Executive Officer & Director
Adrian Adams Chairman
Raffi Asadorian CFO & Principal Accounting Officer
Pamela Pierce Palmer Director & Chief Medical Officer
Mark Allen Wan Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ACELRX PHARMACEUTICALS INC82.72%224
GILEAD SCIENCES3.13%95 774
VERTEX PHARMACEUTICALS18.19%45 132
REGENERON PHARMACEUTICALS3.29%40 728
NEUROCRINE BIOSCIENCES, INC.54.99%10 622
SAREPTA THERAPEUTICS INC173.09%10 096